Trial Profile
Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Feb 2023
Price :
$35
*
At a glance
- Drugs Selumetinib (Primary) ; Iodine-131
- Indications Carcinoma; Thyroid cancer
- Focus Therapeutic Use
- 31 Jan 2023 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 18 Mar 2022 Planned End Date changed from 20 Feb 2022 to 31 Dec 2022.
- 19 May 2021 Planned End Date changed from 1 Aug 2021 to 20 Feb 2022.